Antibe Therapeutics named Yung Wu to its board of directors and completed enrollment for its phase 2 clinical trial.
Here are four things to know:
1. Mr. Wu is the managing director of NFQ Ventures, a private equity firm. He has founded seven companies over the course of his career.
2. He also serves as a director on the board of Green Shield, a health benefits insurance and financial services company.
3. Antibe focuses on developing medications for pain and inflammation. Its lead drug is ATB-346.
4. The company recent recruited the final patient for its phase 2 clinical trial examining the efficacy of ATB-346 in patients with osteoarthritis.